Qube Research & Technologies LTD Otonomy, Inc. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 01, 2022	SELL	$1.69 - $2.31 $25,743 - $35,188	-15,233 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.22 - $2.2 $18,584 - $33,512	15,233 New	15,233 $29,000
Q2 2021 Aug 13, 2021	SELL	$2.06 - $2.67 $107,896 - $139,846	-52,377 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$2.49 - $6.23 $259,761 - $649,926	-104,322 Reduced 66.57%	52,377 $134,000
Q4 2020 Feb 16, 2021	BUY	$3.48 - $6.47 $336,178 - $625,021	96,603 Added 160.75%	156,699 $1.01 Million
Q3 2020 Nov 12, 2020	BUY	$3.16 - $4.36 $124,769 - $172,150	39,484 Added 191.56%	60,096 $243,000
Q2 2020 Aug 14, 2020	BUY	$1.87 - $3.84 $38,544 - $79,150	20,612 New	20,612 $75,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.